Navigation Links
From genomic data to new cancer drug
Date:10/27/2011

New discoveries about follicular lymphoma, a currently intractable form of cancer, highlight the power of functional genomics in cancer gene discovery. A report in the Oct 28th issue of Cell, a Cell Press publication, demonstrates how genetic insights can be translated directly into therapies.

The findings are but one example of what has now become possible given the avalanche of data on cancer genomes.

"With access to tumor genomic data, suddenly we can do this; we know what has changed, and the question now is to define which changes are really important," says Hans-Guido Wendel of Memorial Sloan-Kettering Cancer Center, and senior author of this study. "With that information, we can start to develop new therapies."

Wendel's group has developed a way to target and shrinks tumors when delivered to mice with an incurable form of lymphoma. Loss of the anti-cancer protein known as EPHA7 (ephrin receptor A7) is an important driver of the disease, the new evidence shows.

"We went all the way from genomic data to a potential new drug," said Wendel. "EPHA7 was not on anyone's radar screen for lymphoma. Now it is."

Wendel's team focused their attention on a portion of chromosome 6 that is commonly lost in human patients and is related to poor outcomes. But such large-scale changes can only tell you so much. "Tumors often acquire complex genomic aberrations including gains and losses of large sections or even entire chromosomes," the researchers said. "Identifying the target gene or genes from such complex genomic changes remains a significant challenge."

They used a method called RNA interference to silence genes in that stretch of the genome. That effort led them to EPHA7, a tumor suppressor protein that is shed from the surface of lymphocytes.

It is important that EPHA7 is a soluble factor, Wendel explained. "You can purify it, put it in a bottle, and see if it can be administered as a drug."

When the researchers injected EPHA7 into mice with human tumors, those tumors shrunk. They found that a particularly effective way to deliver EPHA7 to cancer cells is to fuse it with an antibody that specifically targets lymphomas.

The researchers say EPHA7 has immediate therapeutic potential, although they intend to pursue smaller versions of the protein that might be easier to make. There is also reason to think EPHA7 may ultimately have promise for the treatment of other forms of cancer as it binds a protein with links to breast and ovarian cancer.


'/>"/>
Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Dana-Farber, Brigham and Womens launch large-scale genomic database project
2. Structural Genomics Project creates blueprint for infectious disease and biodefense research
3. Lung tumors in never-smokers show greater genomic instability than those in smokers
4. Novel analysis method organizes genomic cancer data
5. Genomic test shows promise as chemotherapy response, survival predictor for women with breast cancer
6. Genomic signature in post-menopausal women may explain why pregnancy reduces breast cancer risk
7. New genomics research investigates metastatic childhood cancers
8. Promise of genomics research needs a realistic view
9. NHGRI charts course for the next phase of genomics research
10. Tufts University calls for moderate approach to teaching personalized genomic testing
11. Genomic markers may head off thousands of thyroid surgeries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North ... month of February, patients who visit Hamlin Dental Group will receive a ticket for ... at the Cheesecake Factory. , Tickets are available for routine dental visits and ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data and ... Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight ... due in part to an array of circumstances including the use of multiple ...
(Date:2/23/2017)... Lincoln, RI (PRWEB) , ... February 23, 2017 ... ... announced today a new partnership with the Rhode Island Consortium for Autism Research ... provide an opportunity for children with autism spectrum disorder (ASD) to see films ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Top cosmetic and ... Patriot program today with a new Indiegogo campaign . Individuals are now ... veterans in the Los Angeles area, either as a participating patient or through an ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... YORK , February 23, 2017 ... in the United States . According to ... the cannabis industry is expected to create 283,422 jobs by ... percent compounded over the next four years. The accelerating pace ... drives the growth of legal cannabis market, which will further ...
(Date:2/23/2017)... York , February 23, 2017 ... Holter Monitor Market are GE Healthcare, Koninklijke Philips N.V., ... about 48% in the global market in 2015. Strong ... two key factors assessed to be aiding these players ... Research states that the players in the global market ...
(Date:2/23/2017)... 2017   SeraCare Life Sciences , a ... diagnostics manufacturers and clinical laboratories, is announcing an ... NGS-Based Tests" to be hosted by GenomeWeb ... Eastern Standard Time (US). The goal ... for improved performance and global standardization in the ...
Breaking Medicine Technology: